UNSPSC 51361904: Aprobarbital

This classification denotes a barbiturate with the molecular formula C10H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0YKG9L6RF, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-, monosodium salt but generally known as aprobarbital, which bears US NIH Compound Identifier 6464. Aprobarbital most often comes in base, o,o-dimethyl-epoxide, natrium, and sodium forms.

UNSPSC 51361904 Aprobarbital is a Commodity code that nominally covers a specific barbiturate pharmaceutical, but recent state and local procurement activity shows minimal relevant recent solicitations tagged to this code. The three most recent opportunities posted under or near this classification address broader pharmaceutical and naloxone procurement rather than aprobarbital specifically: Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023); Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026); and Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026). The mismatch between the code's narrow scope and the actual solicitation activity suggests either tagging inconsistency or that aprobarbital represents a minimal or non-existent procurement line for state and local health agencies. State and local issuing bodies acquiring pharmaceuticals tend to do so through broader, family-level purchasing vehicles and cooperative purchasing alliances rather than solicitations for individual active ingredients.

Geographic activity appears concentrated in the Southeast and multi-state cooperative vehicles: Seminole County in Florida is the single jurisdiction-specific buyer among recent postings, while the Minnesota and Texas opportunities span multiple jurisdictions through state-level purchasing and cooperative alliances. The Minnesota MMCAP RFP involves participating state and local facilities across multiple states including Oregon, and requires vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with cGMP and Drug Supply Chain Security Act compliance. The Texas HHS Commission RFI is exploratory in nature, designed to inform future solicitation strategy around direct-to-manufacturer prescription relationships rather than to solicit aprobarbital specifically. Bidders pursuing this code should expect cooperative purchasing and multi-state vehicles to dominate activity, and should verify that procurement opportunities genuinely address aprobarbital rather than broader pharmaceutical categories before investing in response preparation.